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Abstract While reliable detection of illicit drug use is para-
mount to the field of addiction, current methods involving self-
report and urine drug screens have substantial limitations that
hinder their utility. Wearable biosensors may fill a void by
providing valuable objective data regarding the timing and con-
texts of drug use. This is a preliminary observational study of
four emergency department patients receiving parenteral opioids
and one individual using cocaine in a natural environment. A
portable biosensor was placed on the inner wrist of each subject,
to continuously measure electrodermal activity (EDA), skin tem-
perature, and acceleration. Data were continuously recorded for
at least 5 min prior to drug administration, during administration,
and for at least 30 min afterward. Overall trends in
biophysiometric parameters were assessed. Injection of opioids
and cocaine use were associated with rises in EDA. Cocaine
injection was also associated with a decrease in skin temperature.
Opioid tolerance appeared to be associated with a blunted phys-
iologic response as measured by the biosensor. Laterality may be
an important factor, as magnitude of response varied between
dominant and nondominant wrists in a single patient with bilat-
eral wrist measurements. Changes in EDA and skin temperature
are temporally associated with intravenous administration of
opioids and cocaine; the intensity of response, however, may
vary depending on history and extent of prior use.
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Introduction
The detection of illicit drug use is of great interest to the field
of addiction medicine given that relapse is a key indicator of
outcomes. At present, detecting drug use relies upon data
obtained from testing biological specimens (e.g., qualitative
screens of urine for drugs of abuse) or self-report. While these
approaches are useful, they have methodological shortcom-
ings [1–4]. First, both methods obtain discontinuous data that
cannot provide real-time information about drug using behav-
iors. Second, neither method allows researchers to reliably
discern drug use patterns over time in order to better evaluate
the time course of treatment effects. Third, neither method has
been adapted into smartphones or other mobile health devices,
which could integrate drug use data into the affective and
environmental contexts surrounding drug use [1, 2]. Finally,
neither method currently provides an opportunity for real-time
intervention or analysis of triggers, which is currently a sub-
stantial limitation of addiction treatment.
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Portable biosensors have the potential to revolutionize the
field of addiction by providing continuous data streams to
detect the timing, location, contexts, and durations of drug
use in individuals under treatment. These small, unobtrusive
electronic devices are easily applied and worn, can detect
important physiologic parameters that are expected to change
with substance use (such as electrodermal activity [EDA],
physical movement of the body in three dimensions [acceler-
ation], and skin temperature) and can wirelessly stream infor-
mation to a smartphone to trigger behavioral interventions
precisely at the moment of greatest need [1, 4]. The use of
portable biosensors to enhance monitoring/intervention strat-
egies have been described in other at-risk populations, includ-
ing HIV positive individuals, epilepsy patients, and those
diagnosed with PTSD [1, 4, 5]. Few data, however, describe
the biometric profile of individuals actively using recreational
drugs, and this is imperative to define before biosensors can be
utilized in a meaningful way in drug treatment. In this pilot
study, we sought to evaluate the biometric changes associated
with the injection of cocaine and opioids.
Methods
All protocols were approved by the appropriate institutional
review board. A Q sensor™ (Affectiva, Waltham, MA) was
utilized for all data collection. The sensor is approximately 4
by 5 cm; it is worn on the volar aspect of the wrist and secured
by a Velcro band (Fig. 1). The Q sensor continuously records
EDA measures in microsiemens (μS), skin temperature in
degree Celsius, and acceleration in units g (SI unit of acceler-
ation). Recordings were taken at a sample rate of 8 readings
per second. To assess for measurable physiologic changes and
to examine the feasibility of technology deployment with data
collection in vivo, two separate protocols were used to recruit
emergency department (ED) patients and a field subject, re-
spectively, as outlined below.
Emergency Department Protocol: Biometrics of Opioid
Use The University of Massachusetts Institutional Review
Board approved the experimental protocol for measurement
of biometric profiles of opioid administration in ED patients.
Inclusion criteria were (1) age 18–90 years old, (2) chief
complaint of acute pain, (3) a clinician’s written order for
intravenous opioid analgesic, and (4) ability to provide con-
sent. Exclusion criteria were (1) inability to wear a biosensor,
(2) musculoskeletal causes of pain, (3) pregnancy, (4) inability
to consent, or (5) upper extremity amputation. Potential sub-
jects were informed that the purpose of the study was to
determine the utility of the device to detect opioid use by
measuring physiologic change after known exposure. After
obtaining informed consent, research staff placed a portable
biosensor first on the nondominant wrist unless this interfered
with medical treatment (i.e., intravenous lines), then it was
placed on the dominant wrist if such interference was identi-
fied. EDA, skin temperature, and acceleration were continu-
ously recorded before, during, and 30 min after intravenous
opioid administration. Demographic data including age, gen-
der, hand dominance, and history of opioid use, in addition to
biosensor responses to drug administration were recorded.
Opioid use history was ascertained from patient report, and
supplemental prescription history data from the institution’s
electronic medical record was included as well.
Field Deployment Protocol: Biometrics of Cocaine Use The
Massachusetts Institute of Technology Committee on the Use
of Humans as Experimental Subjects and the University of
Massachusetts Medical School Institutional Review Board
approved the experimental protocol. Recruitment was per-
formed with the assistance of a community outreach program
that referred individuals with active substance abuse. Because
IRB approval was granted for application of biosensors to
individuals pursuing normal activities in their daily lives, only
subjects who were disinterested in seeking drug treatment
were referred. Inclusion criteria were (1) age 18–90 years old
and (2) ability to provide consent. Exclusion criteria were (1)
inability to wear a biosensor, (2) pregnancy, (3) inability to
consent, or (4) upper extremity amputation. Potential subjects
were informed that the purpose of the study was to measure
physiologic changes associated with normal daily activities and
to determine the feasibility of procedures surrounding deploy-
ment of the sensor; they were shown the sensor prior and
briefed on the device capabilities. After an IRB-mandatedFig. 1 Picture of subject wearing Q sensor
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encouragement to avoid drug use and other unsafe activities,
the sensor was placed on the subject’s dominant wrist. The
subject was instructed to come back to the community outreach
site in 4 h to return the sensor, or sooner if any concerns arose.
At the end of data collection, a timeline follow back inter-
view was conducted to determine activities at various points
during the period the subject wore the sensor.
Results
Emergency Department Data During this portion of the study,
the ambient hospital temperature and humidity were main-
tained at approximately 65 °F and 50 %, respectively. Four
subjects who met the inclusion criteria were approached, and
all consented to enrollment. Demographic characteristics are
listed in Table 1. All subjects were supine in gurneys and none
engaged in any significant physical activity during the record-
ing period. The subjects denied any discomfort associated
with the sensors. One subject questioned whether the sensor
would be perceived by staff as a court-ordered electronic
monitoring device, but nonetheless chose to participate in
the study. The remaining three subjects did not perceive any
stigma associated with the device.
The q sensor tracing and summary data are presented in
Figs. 2, 3, 4, 5, and 6 and Table 1.
In subject 1, an opioid naïve 82-year-old man, a rise in
EDA from a baseline of 4.5 μS was noted immediately
following the administration of 4 mg IV morphine; the EDA
peaked at approximately 60 μS at 6 min post-intervention,
then gradually declined toward baseline. This patient’s EDA
level remained elevated at the end of the recording period. The
sensor electrode temperature remained constant throughout
the session with the exception of the typical rise from room
temperature to skin temperature shortly after the sensor was
placed on the patient. The patient reported almost complete
relief in pain after opioid administration (Fig. 2).
Subject 2, a 47-year-old man, reported an approximately 2-
week history of oxycodone use following a recent surgical
procedure, but denied other prior opioid use history. After
1 mg IV hydromorphone administration, his measured EDA
rose from a baseline of 3.4 μS to a peak of 12.2 μS approx-
imately three minutes post administration. No change in body
temperature was noted. The patient reported only a small
decrease in pain, and a second dose of 1 mg IV
hydromorphone was administered 25 min later (Fig. 3).
Subject 3 was a 43-year-old woman who reported chronic
use of opioid analgesics. She presented with abdominal pain,
and treating clinicians expressed concern that she distorted her
symptoms to ensure narcotic administration. Intravenous ad-
ministration of 1 mg hydromorphone produced no change in
EDA, but a gradual 4 °C upward trend in skin temperature
occurred over a 10-min period after administration. The pa-
tient reported no change in her pain following hydromorphone
administration and requested additional medication (Fig. 4).
Subject 4 was a 72-year-old man with a history of chronic
opioid use including oral oxycodone 1–3 times daily over the
past year, with sporadic use of hydrocodone in the preceding
years. Given the dramatic intersubject differences in the early
portion of the study, combined with new data emerging from
other ongoing studies, the protocol was adjusted to include
bilateral wrist sensors during this subject’s participation. Fol-
lowing the administration of 4 mg of morphine, a small
increase in EDAwas noted in both wrists. A smooth, gradual
increase was noted in the dominant wrist from a baseline of
0.5 to 0.8 μS. A more stepwise increase was seen in the
nondominant wrist from a baseline of 0.9 μS to a peak of
1.6 μS over 16 min. Skin temperature also increased, more
prominently in the nondominant wrist. The patient reported
minimal improvement in his pain (Fig. 5).
Field Data Because of concerns that the device might
reveal an individual’s location to law enforcement, only
one person agreed to participate in the pilot field study
out of the two potential subjects approached. The field
study subject was a left-hand-dominant 53-year-old man
with a 20-year history of daily parenteral cocaine use.
He reported no medical problems other than drug use;
he denied taking any prescription or over-the-counter
medications. He wore the sensor on his left wrist for a
continuous 5-hour period. Data were collected between
Table 1 Summary characteristics of participants
Patient Handedness Age Gender History of use Intervention Sensor wrist Pre-EDA Post-EDA Response
1 Right 82 M Opioid naïve 4 mg morphine Left 4.5 60.0 Complete resolution
2 Left 47 M Recent short term
opioid use
1 mg hydromorphone Right 3.4 12.2 Moderate improvement
3 Left 42 F Chronic opioid use 1 mg hydromorphone Left 0.2 0.2 No improvement
4 Right 72 M Chronic opioid use 4 mg morphine Right 0.5 0.8 Minimal improvement
Left 0.9 1.6
Field Left 53 M Chronic cocaine Self administered- cocaine Left 1.5 10.5 N/A
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10 a.m. and 3 p.m.; the air temperature averaged 78 °F
with humidity of 40 %. During the timeline follow-back
interview, the subject reported that he had eaten a snack
before injecting cocaine about 40 min after leaving the
community outreach site. He did not report engaging in
physical activity aside from walking for approximately
0.5 mi during the data collection period.
The study subject reported that he did not perceive any
stigma associated with the biosensor even though he was
wearing a short-sleeved shirt and was around familiar and
unfamiliar persons during the data collection period. He also
reported that he received no queries about the purpose of the
device even though he was in locations where illegal activities
occurred (e.g., the buying and using of drugs).
Data from the sensor was downloaded and a portion of the
5-hour recording is presented in Fig. 6. Review of the data
demonstrates a dramatic increase in electrodermal activity of
approximately 10 μS accompanied by decrease in skin tem-
perature of approximately 1–2 °F and an increase in acceler-
ation (i.e., increased physical movement). This upsweep in
electrodermal activity is consistent with the reported time of
cocaine injection as identified in the timeline follow-back
interview.
Discussion
In this small pilot study, both intravenous cocaine and opioid
administration were temporally associated with notable bio-
metric changes, primarily an increase in EDA, that were
detectable by wearable biosensors in relatively controlled
environments. Skin temperature and acceleration parameters
also showed some change, although less pronounced, partic-
ularly in our field participant using cocaine. These findings
supports the ability of mobile biosensors to detect episodes of
drug use in real time, with the ultimate goal of detecting drug
use as it occurs in natural environments. Having a direct,
continuous, and real-time measure of drug use episodes offers
an advantageous supplement to existing methods by
Fig. 2 EDA scale varies between
tracings to emphasize the shape of
the curve and is labeled on the
upper right portion of the tracing.
Each tracing consist of three
panels: top panel: electrodermal
activity in μS; middle panel:
temperature in °C; and lower
panel: Acceleration in unit g.
Participant 1. Please note, time of
day is shown on the top axis, and
an event marker along the top of
the screen image delineates the
time of intravenous opioid
administration (where applicable)
Fig. 3 Participant 2
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providing the opportunity for real-time feedback and interven-
tion. When linked to environmental and behavioral events
surrounding relapsing drug use, mobile biosensors may allow
drug abuse researchers and clinicians to tailor interventions to
highly specific contexts, including the delivery of such inter-
ventions precisely at the moment of greatest need.
It is important to underscore that any psychological
or physiological stress is expected to produce an in-
crease in SNS activity, and thus alterations in EDA,
skin temperature, and acceleration. These phenomena
have been documented in numerous studies evaluating
the measurable stress responses in humans during driv-
ing, public speaking, or simple everyday activities that
people report as stressful [6–8]. These responses are
notably less dramatic that those associated with drug
administration. Figure 7 provides an example of a per-
son with PTSD who is exposed to a stimulus known to
elicit stress and anxiety. In comparison, the biometric
pattern from subject 5 demonstrates a more robust de-
crease in skin temperature that is consistent with the
vasoconstrictive effects of cocaine. Because of the tem-
poral association of physiologic change with drug ad-
ministration, the magnitude of the EDA response, the
graded biometric response in tolerant individuals, and
the inverse relationship between skin temperature chang-
es in drug use and stress, these sensors appear capable
of detecting isolated opioid and cocaine use in human
subjects.
Compared with the robust increases in EDA that
occurred in opioid-naïve persons, diminished biometric
responses were observed among individuals with self-
described chronic opioid use. Variation in biometric
response to opioids among the four ED subjects high-
lights the importance of confounding variables in inter-
pretation of physiologic data. Of particular interest is
the apparent relationship between previous opioid use
and perception of clinical effectiveness (as indicated by
patient-reported analgesia) with EDA response. Subjects
with extensive opioid use, lower levels of reported pain
relief, and, presumably, tolerance to this class of drug’s
pharmacologic effects showed little to no EDA change
at the doses prescribed, while opioid-naïve or less ex-
perienced patients demonstrated more dramatic changes.
This finding raises the possibility of developing an
objective measure of opioid tolerance using biosensors
that could guide clinician prescribing.
Fig. 4 Participant 3
Fig. 5 Participant 4: left
(nondominant) and right
(dominant) wrist tracings
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Cerebral lateralization and resultant differences in EDA
measured in bilateral limbs of the same individual has been
well documented [6, 9] Complex differences in EDA mea-
surements with respect to laterality have been observed in
normal subjects performing a variety of physical and cognitive
tasks [9, 10]. Furthermore, studies looking at stress responses
and EDA demonstrate conflicting results, with some demon-
strating exaggeration of bilateral differences and others show-
ing decreased variability or even pattern reversal [11]. Striking
asymmetries in bilateral EDA measurements appear to be
more pronounced specifically in periods of high anxiety or
perceived threat [6]. Interestingly, the presence of stereotyped
lateralizing behaviors that are considered indicative of
nigrostriatal asymmetry has been linked with differential pat-
terns of drug abuse in animal models [12], but laterality in
EDA response to substance use has not been documented.
Factors that may influence magnitude of response include
hand dominance, gender, and preexisting CNS pathology,
such as traumatic brain injury [11, 13]. It is hypothesized that
multiple areas of the CNS contribute to the EDA at a
given location in the body, some of which discharge in
an ipsilateral fashion and others in a contralateral fash-
ion, potentially leading to differences in bilateral expres-
sion patters with various physiologic stimuli [6]. In the
single ED patient wearing bilateral sensors, comparable
trends were observed bilaterally (e.g., the EDA in-
creased in both wrists), but this degree of change was
greater in the nondominant wrist measurement. Cerebral
hemispheric dominance and laterality of EDA expres-
sion will undoubtedly add a layer of complexity to the
application of this technology to drug detection and will
require further exploration.
Clinical trials for substance abuse interventions that
employ wearable biosensors require that this equipment
be distributed to drug users who may lose these expen-
sive devices or may have an incentive to sell them. The
distribution, use, and recovery of a wearable biosensor
from an active drug user in this study is consistent with
the findings of previous research using cellphones and
personal data assistants as successful data collection
devices for opioid and cocaine abusers [14–17]. In
contrast to smartphones, personal data assistants, and
Fig. 6 Field participant (cocaine
use)
Fig. 7 Example of EDA tracing
of severe stress reaction
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beepers, wearable biosensors are potentially stigmatizing
mobile electronic devices. Although the avidity with
which active drug users accept wearable biosensors can-
not be ascertained from this study, these data suggest
the feasibility of recovering an expensive ubiquitous
computing device such as the biosensor.
Limitations
The main limitation of this study is the inability to generalize
these findings due to small sample size in this pilot and the fact
that only a single subject was recorded in a natural setting
outside of a healthcare facility. Also, the dosing of opioid
analgesic based on providers’ discretion likely differs from
subject initiated recreational use. Unilateral data was obtained
on four of the five patients and may have missed a more brisk
response on the contralateral side. Lack of prolonged data
recording on individuals prior to drug administration makes
it difficult to interpret how much these changes would differ
from baseline variability in EDA.
Conclusion
In this small pilot study, wearable biosensors were able to
detect the administration of opioids as well as cocaine, were
acceptable to our subjects and were feasible to use in this
capacity. The nature and intensity of patients’ biometric re-
sponse to drug administration, in a small sample of patients,
suggests that the physiologic response to opioids may
vary inversely with opioid tolerance. Wearable biosen-
sors show promise as adjuncts to drug abuse treatment
research to help determine the efficacy of relapse pre-
vention interventions. Follow-up studies are underway
to explore both the feasibility and accuracy of this
approach using larger sets of data, natural use settings,
and various levels of drug exposure history.
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